The potential of proton beam radiation therapy in head and neck cancer

Ask, Anders; Björk‐Eriksson, Thomas; Zackrisson, Björn; Blomquist, Erik; Glimelius, Bengt

doi:10.1080/02841860500355991

Cited by 21 publications

(2 citation statements)

References 59 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, several reviews indicated that based on clinical evidence it remains unclear, mainly because of the absence of randomized trials, whether particle therapy is superior over radiotherapy with photons in HNC. [13][14][15][16][17][18][19][20] This makes it difficult to decide whether particle therapy should be implemented as a (routine) treatment in clinical practice. 21 However, decisions need to be made.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia

Akurathi¹,

Dubois²,

Lieuwes³

et al. 2010

Nuclear Medicine and Biology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Synthesis and biological evaluation of a 99mTc-labelled sulfonamide conjugate for in vivo visualization of carbonic anhydrase IX expression in tumor hypoxia

Akurathi¹,

Dubois²,

Lieuwes³

et al. 2010

Nuclear Medicine and Biology

View full text Add to dashboard Cite

show abstract

“…Several studies have been though conducted trying to identify the cost-benefit of proton therapy and the type of cancer patients that might benefit from proton therapy [11, 12]. Several investigations concluded that for approximately 15% of cancer patients treated with radiation therapy, proton therapy might be cost-effective.…”

Section: Current Status and Gapsmentioning

confidence: 99%

Quo Vadis Radiotherapy? Technological Advances and the Rising Problems in Cancer Management

Allen

Bezak

Marcu

2013

BioMed Research International

View full text Add to dashboard Cite

Purpose. Despite the latest technological advances in radiotherapy, cancer control is still challenging for several tumour sites. The survival rates for the most deadly cancers, such as ovarian and pancreatic, have not changed over the last decades. The solution to the problem lies in the change of focus: from local treatment to systemic therapy. The aim of this paper is to present the current status as well as the gaps in radiotherapy and, at the same time, to look into potential solutions to improve cancer control and survival. Methods. The currently available advanced radiotherapy treatment techniques have been analysed and their cost-effectiveness discussed. The problem of systemic disease management was specifically targeted. Results. Clinical studies show limited benefit in cancer control from hadron therapy. However, targeted therapies together with molecular imaging could improve treatment outcome for several tumour sites while controlling the systemic disease. Conclusion. The advances in photon therapy continue to be competitive with the much more expensive hadron therapy. To justify the cost effectiveness of proton/heavy ion therapy, there is a need for phase III randomised clinical trials. Furthermore, the success of systemic disease management lies in the fusion between radiation oncology technology and microbiology.

show abstract